Suppr超能文献

复发性、转移性或新发原发性肿瘤的三维适形或立体定向再程放疗。108例患者分析。

Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients.

作者信息

Jereczek-Fossa Barbara A, Kowalczyk Anna, D'Onofrio Alberto, Catalano Gianpiero, Garibaldi Cristina, Boboc Genoveva, Vitolo Viviana, Leonardi Maria Cristina, Cambria Raffaella, Orecchia Roberto

机构信息

Division of Radiotherapy, European Institute of Oncology, Milan, Italy.

出版信息

Strahlenther Onkol. 2008 Jan;184(1):36-40. doi: 10.1007/s00066-008-1783-9.

Abstract

PURPOSE

To analyze the outcome of reirradiation of recurrent/metastatic or new primary tumors with three-dimensional conformal (3D-CRT) or stereotactic (SRT) techniques.

PATIENTS AND METHODS

108 patients reirradiated between 01/2002 and 01/2005 at the European Institute of Oncology, Milan, Italy, were analyzed. Primary diagnosis included breast, lung, head/neck, urologic tumors, and other primaries. Curative and palliative intent were applied to 27 (25%) and 81 patients (75%), respectively. 3D-CRT and SRT were employed in 57 (53%) and 48 patients (44%), respectively, up to a mean dose of 23 Gy.

RESULTS

Median follow-up was 7 months (range, 1-50 months). Response, stabilization, and progression were observed in 33%, 36%, and 17% of patients, respectively (15 patients were not evaluable). No severe toxicity was reported. Median overall survival amounted to 32.6 months and was longer in patients treated with curative intent.

CONCLUSION

A small portion of patients can be cured with a second course of radiotherapy, and in many cases, palliation can be obtained. Low toxicity of reirradiation with use of modern techniques should allow for the delivery of higher doses and, in consequence, lead to an improvement in reirradiation outcome.

摘要

目的

分析采用三维适形放疗(3D-CRT)或立体定向放疗(SRT)技术对复发性/转移性或新发原发性肿瘤进行再程放疗的疗效。

患者与方法

对2002年1月至2005年1月间在意大利米兰欧洲肿瘤研究所接受再程放疗的108例患者进行分析。原发诊断包括乳腺癌、肺癌、头颈部肿瘤、泌尿系统肿瘤及其他原发性肿瘤。分别对27例(25%)患者采用根治性放疗,81例(75%)患者采用姑息性放疗。分别有57例(53%)和48例(44%)患者采用3D-CRT和SRT,平均剂量达23 Gy。

结果

中位随访时间为7个月(范围1 - 50个月)。分别有33%、36%和17%的患者观察到缓解、病情稳定和病情进展(1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验